Technology area: Biotechnology & Pharmaceuticals
21 pending office actions • 18 art units • 21 examiners • 0 of 21 (0%) have an AI response strategy ready • 24 patents granted in the last 365 days
The Scripps Research Institute has 21 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 21 examiners across 18 art units, showing a highly distributed docket with several matters sharing technical examination groups but not examiners.
DRISCOLL, LORA E BARNHART is the busiest examiner, with 1 pending office action. No examiner accounts for multiple actions in the available data, so prosecution management should emphasize technology and art-unit organization, along with file-specific review of each examiner’s position.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (10%) |
| §103 only | 2 (10%) |
| §102 only | 3 (14%) |
| §112 only | 1 (5%) |
| Double-patenting only | 1 (5%) |
| Double-patenting + other | 3 (14%) |
| Multi-statute (no §101) | 9 (43%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DRISCOLL, LORA E BARNHART | 1 | 31.8% | +20.8% |
| HASTINGS, ALISON AZAR | 1 | 62.5% | +42.1% |
| TSAY, MARSHA M | 1 | 45.5% | +52.8% |
| GRIZER, CASSANDRA SENN | 1 | 70.0% | +48.0% |
| SCHMIDT, IZABELA MARIA | 1 | 65.7% | +42.7% |
| BUCCINI, MICHELLE CALLAHAN | 1 | — | — |
| JONES, CHRISTINE MICHELLE | 1 | 0.0% | +0.0% |
| NEAGU, IRINA | 1 | 46.7% | +57.2% |
| LEE, ANDREW P | 1 | 48.5% | +22.8% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18327110 | ENGINEERED CELLS AND METHODS OF USE | KELLY, ROBERT M | 2d overdue |
| 17923171 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | SCHACHERMEYER, SAMANTHA LYNN | 65d |
| 18388023 | METHODS FOR MITIGATING AND PREVENTING PROTEOSTASIS-BASED INJURIES | LEE, ANDREW P | 83d |
| 18859759 | MOLECULAR EDITING OF MULTIPLE C-H BONDS LEVERAGING RECOGNITION OF DISTANCE, GEOMETRY AND CHIRALITY | HASTINGS, ALISON AZAR | — |
| 18821631 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HIV INFECTION | GRIZER, CASSANDRA SENN | — |
| 18423804 | Methods, Systems, and Compositions for Diagnosing Transplant Rejection | JONES, CHRISTINE MICHELLE | — |
| 18517049 | PHARMACOLOGICAL DEPLETION OF HEME FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME | NEAGU, IRINA | — |
| 18548635 | HETEROBIFUNCTIONAL COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION AND METHODS FOR THEIR USE | CHANDRAKUMAR, NIZAL S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18388023 | METHODS FOR MITIGATING AND PREVENTING PROTEOSTASIS-BASED INJURIES | LEE, ANDREW P | 83d |
| 19083131 | REENGINEERING MRNA PRIMARY STRUCTURE FOR ENHANCED PROTEIN PRODUCTION | DRISCOLL, LORA E BARNHART | — |
| 18859759 | MOLECULAR EDITING OF MULTIPLE C-H BONDS LEVERAGING RECOGNITION OF DISTANCE, GEOMETRY AND CHIRALITY | HASTINGS, ALISON AZAR | — |
| 18917399 | NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF | TSAY, MARSHA M | — |
| 18821631 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HIV INFECTION | GRIZER, CASSANDRA SENN | — |
| 18627081 | NOVEL KAPPA OPIOID LIGANDS | SCHMIDT, IZABELA MARIA | — |
| 18517049 | PHARMACOLOGICAL DEPLETION OF HEME FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME | NEAGU, IRINA | — |
| 18548635 | HETEROBIFUNCTIONAL COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION AND METHODS FOR THEIR USE | CHANDRAKUMAR, NIZAL S | — |
| Art Unit | Apps |
|---|---|
| 1699 | 2 |
| 3991 | 1 |
| 1656 | 1 |
| 1621 | 1 |
| 1675 | 1 |
| 1682 | 1 |
| 1629 | 1 |
| 1691 | 1 |
| 1625 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19083131 | REENGINEERING MRNA PRIMARY STRUCTURE FOR ENHANCED PROTEIN PRODUCTION | DRISCOLL, LORA E BARNHART | 3991 | §112DPOther | Non-Final OA | — | Pending | Mar 18, 2025 |
| 18859759 | MOLECULAR EDITING OF MULTIPLE C-H BONDS LEVERAGING RECOGNITION OF DISTANCE, GEOMETRY AND CHIRALITY | HASTINGS, ALISON AZAR | — | §102§112Other | Non-Final OA | — | Pending | Oct 24, 2024 |
| 18917399 | NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF | TSAY, MARSHA M | 1656 | §102§103§112DP | Non-Final OA | — | Pending | Oct 16, 2024 |
| 18821631 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HIV INFECTION | GRIZER, CASSANDRA SENN | — | §102§103§112 | Non-Final OA | — | Pending | Aug 30, 2024 |
| 18627081 | NOVEL KAPPA OPIOID LIGANDS | SCHMIDT, IZABELA MARIA | 1621 | DP | Non-Final OA | — | Pending | Apr 04, 2024 |
| 18554340 | NOVEL THERAPIES WITH ENGINEERED EFFECTOR CELLS | BUCCINI, MICHELLE CALLAHAN | 1675 | §102§103§112DP | Non-Final OA | — | Pending | Jan 31, 2024 |
| 18423804 | Methods, Systems, and Compositions for Diagnosing Transplant Rejection | JONES, CHRISTINE MICHELLE | 1682 | §101§103§112DP | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18517049 | PHARMACOLOGICAL DEPLETION OF HEME FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME | NEAGU, IRINA | 1629 | §102§103 | Non-Final OA | — | Pending | Nov 22, 2023 |
| 18388023 | METHODS FOR MITIGATING AND PREVENTING PROTEOSTASIS-BASED INJURIES | LEE, ANDREW P | 1691 | §102§103 | Non-Final OA | 83d | Pending | Nov 08, 2023 |
| 18548635 | HETEROBIFUNCTIONAL COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION AND METHODS FOR THEIR USE | CHANDRAKUMAR, NIZAL S | 1625 | §103§112 | Final Rejection | — | Pending | Sep 01, 2023 |
| 18546217 | SMALL MOLECULE ACTIVATORS OF YAP TRANSCRIPTIONAL ACTIVITY FOR REGENERATIVE ORGAN REPAIR | BRAUN, MADELINE E | 1624 | §103§112 | Non-Final OA | — | Pending | Aug 11, 2023 |
| 18257808 | IMMUNOGENIC COMPOSITIONS | BOESEN, AGNIESZKA | 1672 | §102 | Final Rejection | 70d | Pending | Jun 15, 2023 |
| 18327110 | ENGINEERED CELLS AND METHODS OF USE | KELLY, ROBERT M | 1638 | §102§112Other | Non-Final OA | 2d overdue | Pending | Jun 01, 2023 |
| 18305292 | COILED COIL IMMUNOGLOBULIN FUSION PROTEINS AND COMPOSITIONS THEREOF | NATARAJAN, MEERA | 1643 | §102 | Non-Final OA | — | Pending | Apr 21, 2023 |
| 18044260 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | JARRELL, NOBLE E | 1699 | §101§102§112 | Non-Final OA | — | Pending | Mar 07, 2023 |
| 17923171 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | SCHACHERMEYER, SAMANTHA LYNN | 1693 | §102§103 | Non-Final OA | 65d | Pending | Nov 03, 2022 |
| 17918448 | GUANIDINE-MODIFIED C-TERMINUS VANCOMYCIN COMPOUNDS, COMPOSITIONS AND METHODS | REYNOLDS, FRED H | 1658 | §103Other | Final Rejection | 30d overdue | Pending | Oct 12, 2022 |
| 17617989 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY CONDITIONS | LOCKARD, JON MCCLELLAND | 1647 | §112 | Non-Final OA | — | Pending | Sep 29, 2022 |
| 17826660 | SULFUR (VI) FLUORIDE COMPOUNDS AND METHODS FOR THE PREPARATION THEREOF | OTTON, ALICIA L | 1699 | §102 | Final Rejection | — | Pending | May 27, 2022 |
| 17716848 | COMPOSITIONS AND METHODS FOR IN VIVO SYNTHESIS OF UNNATURAL POLYPEPTIDES | SHIN, DANA H | 1635 | §103Other | Final Rejection | 8d overdue | Pending | Apr 08, 2022 |
| 17263490 | ENGINERRED ANTIBODIES TO HIV ENV | SIFFORD, JEFFREY MARK | 1671 | §103§112 | Non-Final OA | — | Pending | Jan 26, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Scripps Research Institute has 21 pending office actions as of October 2026, spread across 18 art units and 21 examiners.
Lora E Barnhart Driscoll has the most, with 1 of The Scripps Research Institute's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
